Gastroenterology (all articles) | Page 5 of 67 | Links Medicus Content Curation & Alerts in Medicine

New research – Borup et al – Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo controlled, phase 4 clinical trialhttps://t.co/m1r0heRgjX #gitwitter #BAD #diarrhoea pic.twitter.com/zk1TnZFS6b

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) February 7, 2023

Brief Review | Acute mesenteric ischemia

30 Mar, 2023 | 13:44h | UTC

Acute mesenteric ischaemia – British Journal of Surgery

Review | Recompensation in cirrhosis: current evidence and future directions

29 Mar, 2023 | 13:24h | UTC

Recompensation in Cirrhosis: Current Evidence and Future Directions – Journal of Clinical and Experimental Hepatology (free for a limited period)

Cohort Study | Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

29 Mar, 2023 | 13:02h | UTC

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated – Journal of Hepatology

Indian consensus statements on irritable bowel syndrome in adults

27 Mar, 2023 | 13:18h | UTC

Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian eurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

M-A | Efficacy of a restrictive diet in irritable bowel syndrome.

Diet or medication in primary care patients with IBS: the DOMINO study – a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute – Gut

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review – Gastroenterology

RCT: Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet and the gluten-free diet.

10 mistakes in dietary management of irritable bowel syndrome and how to avoid them.

Supplement: Irritable bowel syndrome and related conditions.

RCT: FODMAPs, but not gluten, elicit modest symptoms of irritable bowel syndrome.

RCT: Among patients with diarrhea-predominant irritable bowel syndrome, a low FODMAP diet achieved earlier symptomatic improvements in stool frequency and excessive wind.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Guidelines for the treatment of irritable bowel syndrome

ACG Clinical Guideline: Management of irritable bowel syndrome

M-A: Efficacy of a low-FODMAP diet in adult irritable bowel syndrome

Phase 2 RCT | Semaglutide did not improve fibrosis in NASH-related cirrhosis

27 Mar, 2023 | 13:01h | UTC

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial – The Lancet Gastroenterology & Hepatology

Commentary: Semaglutide Well-Tolerated, But Shows Lack of Improvement in Liver Fibrosis – HCP Live

Commentary on Twitter

New research – Loomba et al – Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialhttps://t.co/qkydKMpVfO #NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba pic.twitter.com/2A1dylSiq3

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 17, 2023

Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy

23 Mar, 2023 | 13:11h | UTC

Summary: This study investigated the association between estimated life expectancy, surveillance colonoscopy findings, and follow-up recommendations among older adults. The study utilized data from the New Hampshire Colonoscopy Registry and included adults over 65 who underwent colonoscopy for surveillance after prior polyps.

Life expectancy was estimated using a validated prediction model and categorized into three groups: less than 5 years, 5 to less than 10 years, and 10 or more years.

Out of the 9,831 adults included in the study, 8% had advanced polyps or CRC. Among the 5,281 patients with available recommendations, 86.9% were advised to return for a future colonoscopy. Surprisingly, 58.1% of older adults with less than 5 years of life expectancy were also recommended to return for future surveillance colonoscopy.

The study concluded that many older adults with limited life expectancy are still recommended for future surveillance colonoscopy. This data could help refine decision-making about pursuing or stopping surveillance colonoscopy in older adults with a history of polyps.

Article: Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults – JAMA Internal Medicine (link to abstract – $ for full-text)

JAMA Patient Page: What Should I Know About Stopping Routine Cancer Screening?

Commentary on Twitter

Findings suggest that recommending against future surveillance colonoscopy in older adults with low-risk colonoscopy findings and/or limited life expectancy should be considered more frequently than is currently practiced. https://t.co/7jKpYyuZON

— JAMA Internal Medicine (@JAMAInternalMed) March 13, 2023

Guidelines for post polypectomy colonoscopic surveillance

22 Mar, 2023 | 13:31h | UTC

Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 revised edition – Intestinal Research

British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines – Gut

Consensus Statement: U.S. Multi-Society Task Force on Colorectal Cancer now suggests average-risk CRC screening begins at age 45.

USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.

ACG Clinical Guidelines: Start colorectal cancer screening at 45

Evidence-based clinical practice guidelines for management of colorectal polyps – Journal of Gastroenterology

Meta-analysis: Risk of colorectal cancer and cancer related mortality after detection of low-risk or high-risk adenomas, compared with no adenoma, at index colonoscopy

Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer – Gastroenterology

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – Endoscopy

RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease

21 Mar, 2023 | 13:38h | UTC

Summary: The TREATY-FLD randomized clinical trial investigated the effects of time-restricted eating (TRE) versus daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors in patients with obesity and nonalcoholic fatty liver disease (NAFLD).

Participants were randomly assigned to either TRE (eating only between 8:00 am and 4:00 pm) or DCR (habitual meal timing) and instructed to maintain a diet of 1500 to 1800 kcal/d for men and 1200 to 1500 kcal/d for women for 12 months.

The study found that the IHTG content was reduced by 6.9% in the TRE group and 7.9% in the DCR group after 12 months, a difference that was not statistically significant. Furthermore, TRE did not produce additional benefits for reducing body weight, liver stiffness, or metabolic risk factors compared with DCR.

The study supports that the main focus of a diet for managing NAFLD is caloric restriction, which can be achieved both with a TRE strategy or without a TRE strategy with similar results.

Article: Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial – JAMA Network Open

Commentary: Time-Restricted Eating Not More Beneficial Than Calorie Restriction For Patients With NAFLD, Obesity – HCP Live

Commentary on Twitter

TREATY-FLD RCT found that time-restricted eating did not produce additional benefits for reducing intrahepatic triglyceride content, body fat and metabolic risk factors vs daily-calorie-restriction among adults with obesity and NAFLD. https://t.co/it2n4o9Th1

— JAMA Network Open (@JAMANetworkOpen) March 17, 2023

M-A | Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials?

17 Mar, 2023 | 12:55h | UTC

Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials? A systematic review and meta-analysis – UEG Journal

Consensus Paper | Small intestinal bacterial overgrowth in gastrointestinal disorders

16 Mar, 2023 | 13:23h | UTC

Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association – Indian Journal of Gastroenterology

Review | Evidence-based approach to diagnosis and management of abdominal tuberculosis

16 Mar, 2023 | 13:17h | UTC

Evidence-based approach to diagnosis and management of abdominal tuberculosis – Indian Journal of Gastroenterology (if the link is paywalled, try this one)

Commentary from the author on Twitter

Our review on abdominal tuberculosis, where we summarise all the evidence on gastrointestinal tuberculosis and peritoneal tuberculosis, has been published in @ijg_journal
Great effort by @JhaDayakrishna and @menon_mythili https://t.co/spPXILGNw2 pic.twitter.com/SxnGs0n9DE

— Vishal Sharma (@drvishal82) March 11, 2023

CDC recommends HBV screening at least once in a lifetime for all adults aged ≥18 years

13 Mar, 2023 | 15:14h | UTC

Summary: The Centers for Disease Control and Prevention (CDC) has issued new recommendations for screening and testing for hepatitis B virus (HBV) infection in the US.

The recommendations include screening for HBV infection at least once in a lifetime for adults aged ≥18 years and more frequent testing for persons at increased risk for HBV infection. The risk groups include:

Persons incarcerated or formerly incarcerated in jail, prison, or other detention settings.
Persons with a history of sexually transmitted infections or multiple sex partners.
Persons with a history of hepatitis C virus infection.

The CDC recommends using the triple panel (HBsAg, anti-HBs, and total anti-HBc) for initial screening to help identify persons who have an active HBV infection, have resolved infection and might be susceptible to reactivation, are susceptible and need vaccination, or are vaccinated.

Article: Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 – Morbidity and Mortality Weekly Report

Commentaries:

Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination – JAMA

CDC recommends hepatitis B screening for all adults – CIDRAP

CDC Recommends Universal Screening for Hepatitis B Virus – HCP Live

Commentary on Twitter

CDC recommends that all adults get tested for #HepatitisB at least once in their life. Ask your doctor if you’ve been tested. Learn more: https://t.co/kLBZyQYZtQ @CDCMMWR pic.twitter.com/EBkQ9s4MsQ

— CDC (@CDCgov) March 9, 2023

RCT | Induction therapy with olamkicept vs. placebo in patients with active ulcerative colitis

13 Mar, 2023 | 14:48h | UTC

Effect of Induction Therapy With Olamkicept vs Placebo on Clinical Response in Patients With Active Ulcerative Colitis: A Randomized Clinical Trial – JAMA (free for a limited period)

Commentary on Twitter

Among patients with active ulcerative colitis, biweekly infusion of olamkicept 600 mg, but not 300 mg, resulted in a greater likelihood of clinical response at 12 weeks compared with placebo. https://t.co/I9h3jTZxlL pic.twitter.com/hgMvFhdzDa

— JAMA (@JAMA_current) March 8, 2023

Minimum platelet count threshold before invasive procedures in cirrhosis: evolution of the guidelines

13 Mar, 2023 | 14:36h | UTC

Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines – World Journal of Gastrointestinal Surgery

AASLD guidance on the clinical assessment and management of nonalcoholic fatty liver disease

10 Mar, 2023 | 14:36h | UTC

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease – Hepatology

Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – Zeitschrift für Gastroenterologie

AGA Clinical Practice Update | Diagnosis and management of nonalcoholic fatty liver disease in lean individuals.

Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group – The Lancet Gastroenterology & Hepatology (free registration required)

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association – Arteriosclerosis, Thrombosis, and Vascular Biology

Advancing the global public health agenda for NAFLD: a consensus statement – Nature Reviews Gastroenterology & Hepatology

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease – Gastroenterology

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

M-A | Efficacy of mesalamine in irritable bowel syndrome

9 Mar, 2023 | 13:56h | UTC

Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome – Clinical Gastroenterology and Hepatology

Cohort Study | Endoscopic biopsy with normal mucosa associated with elevated risk of inflammatory bowel disease for at least 30 years

8 Mar, 2023 | 14:10h | UTC

Summary:

This study explored the long-term risk of inflammatory bowel disease (IBD) after an endoscopic biopsy with normal mucosa. The researchers identified individuals in Sweden with a lower or upper gastrointestinal (GI) biopsy of normal mucosa, their matched population references, and unexposed full siblings.

They found that individuals with a previous lower or upper GI biopsy showing normal mucosa were at persistently higher risk of overall IBD, ulcerative colitis, and Crohn’s disease compared to their matched population references and unexposed full siblings, and the increased risk persisted at least 30 years after the biopsy with normal findings.

The findings suggest a substantial symptomatic period before IBD diagnosis, and clinicians should be aware of the long-term increased risk of IBD in those with symptoms requiring GI investigation but with a finding of histologically normal mucosa.

Article: Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden – PLOS Medicine

Commentary: Risk for IBD Remains High After Endoscopic Biopsy With Normal Mucosa – HealthDay

Review | Approach to disorders of gut-brain interaction

8 Mar, 2023 | 14:06h | UTC

Approach to Disorders of Gut-Brain Interaction – Mayo Clinic Proceedings

RCT | Study finds both one-food and six-food elimination diets are effective initial options for eosinophilic esophagitis

7 Mar, 2023 | 13:17h | UTC

Summary:

The article describes a multicenter randomized trial that compared the effectiveness of a one-food elimination diet (1FED – eliminating animal milk) versus a six-food elimination diet (6FED – eliminating animal milk, wheat, egg, soy, fish and shellfish, and peanut and tree nuts) for treating eosinophilic esophagitis in adults.

The study found that both diets were equally effective at achieving histological remission, although the 6FED resulted in a higher proportion of patients achieving complete remission. Patients who did not achieve histological remission with the 1FED could proceed to the 6FED, and 43% had histological remission. For those without response to the 6FED, topical fluticasone propionate induced remission in 82%.

Overall, the study suggests that eliminating animal milk alone is an acceptable initial dietary therapy for eosinophilic esophagitis.

Article: One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

News Release: Forgoing one food treats eosinophilic esophagitis as well as excluding six – National Institutes of Health

Commentary on Twitter

New research – Kliewer et al – One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial https://t.co/Tpm0EPPfx0 #EoE #GItwitter #RareDiseaseDay #CEGIR pic.twitter.com/iUcqIt9Pg5

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) February 28, 2023